Jazz Pharmaceuticals stock price target raised by BofA to $247 on cancer drug

Bank of America (BofA) has reduced its stock price target for Agios Pharma from $54 to $32 following disappointing results from a trial related to sickle cell disease (SCD). This downgrade reflects concerns about the company's future performance and market position.

Bank of America (BofA) has lowered its stock price target for Progressive to $346, attributing this adjustment to the company's growth in auto policy. This decision reflects BofA's assessment of Progressive's market position and future performance potential.

Bank of America (BofA) has lowered its stock price target for Home Depot to $430, citing softness in the professional backlog. This adjustment reflects ongoing challenges the company faces in a sluggish housing market and rising inflation, which have negatively impacted consumer demand. The sentiment surrounding Home Depot's stock remains negative as it grapples with these economic pressures.

A recent Bank of America survey indicates that investors expect the euro to end 2026 within a range of $1.10 to $1.20, compared to its current value of $1.1587. This sentiment reflects a cautious outlook among investors regarding significant fluctuations in the euro-dollar exchange rate.

A recent Bank of America (BofA) survey indicates that investors are increasing their risk exposure despite signals suggesting a potential market downturn. The survey highlights a growing trend among investors to take on more risk, even as cash positions are flashing a 'sell signal.' This juxtaposition raises concerns about market stability and investor sentiment moving forward.